Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis

Frontiers in Public Health

Peng-Fei Zhang¹  Qiu Li¹  Dan Xie² 

[1] Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China;West China Biomedical Big Data Center, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, China;Prenatal Diagnosis Center, Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China;Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China;

关键词: prostate cancer;    enzalutamide;    cost-effectiveness;    androgen deprivation therapy;    first-line;   

DOI  :  10.3389/fpubh.2021.608375

来源: Frontiers

【 授权许可】

CC BY